REG - Victrex PLC - Directorate Change

VictrexAnnouncement

05/04/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220405:nRSE2091Ha&default-theme=true

RNS Number : 2091H  Victrex PLC  05 April 2022

 

 

April 5, 2022

Victrex plc

Directorate change

Victrex appoints Ian Melling of Smith & Nephew plc as Chief Financial
Officer

Ian to succeed Richard Armitage as CFO

Victrex plc is an innovative world leader in high performance polymer
solutions, delivering sustainable products which support CO2 reduction and
bring environmental and societal benefit in multiple end-markets. The Group is
pleased to announce that Ian Melling has been appointed as Chief Financial
Officer (CFO) and as an Executive Director of the Board, to succeed Richard
Armitage.

As previously communicated, Richard will step down as CFO and from the Board
on 27(th) May 2022. Ian will join Victrex and the Board on 4(th) July 2022.
 The appointment follows a diverse and thorough search process. In the
intervening period, Mike Ward, Finance Director, who has been with Victrex for
nine years, will assume the role of interim CFO.

Career history:

Ian Melling, FCA, is a Chartered Accountant and currently Senior
Vice-President, Corporate Finance and R&D for Smith & Nephew plc, the
medical technology company, having served as Interim Chief Financial Officer
during 2020.  Ian has served in a number of senior finance roles in the UK
and internationally for Smith & Nephew, including those with divisional
and functional responsibility, having joined the Group in 2006.  He served as
Senior Vice-President Group Finance for five years until October 2021, prior
to his current role.

 

His other roles have included Vice-President Finance for Spine & Biologics
in the USA. Prior to joining Smith & Nephew plc, Ian was an Audit Manager
for Deloitte in London. He holds a first class Masters degree in Chemistry
from Oxford University.

 

Commenting on the appointment:

Dame Vivienne Cox, Chair of Victrex, said: "The Board is delighted that Ian
has agreed to join Victrex. He is a commercially focused CFO, with listed
company experience and a wealth of knowledge from an innovative global growth
business. His background in Medical will also be beneficial for Victrex, as
this is an end-market where we hold significant value and where we expect to
see good growth over the years ahead. The Board would like to thank Richard
for his contribution to Victrex and we look forward to welcoming Ian in due
course."

 

Jakob Sigurdsson, Chief Executive of Victrex, said: "We are all looking
forward to Ian joining Victrex as we continue to deliver on our Polymer &
Parts strategy, with a strong and growing core business supported by our
potentially game-changing mega-programmes. Our growth opportunities continue
to build and Ian's experience will support us across Industrial and also in
Medical, which we anticipate will become a larger part of the Group in the
future."

 

There is no further information to be disclosed under Listing Rule 9.6.13

 

Notes:

1/ Ian will be appointed on a base salary of £350,000.

 

Enquiries:

Victrex plc:

Andrew Hanson, Director of Investor Relations & Corporate Communications
      +44 (0) 1253 898121

 
             +44 (0) 7809 595831

 

 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions,
focused on the strategic markets of Automotive, Aerospace, Energy &
Industrial, Electronics and Medical. Every day, millions of people rely on
products or applications which contain our sustainable materials, from
smartphones, aeroplanes and cars to oil & gas operations and medical
devices. With over 40 years' experience, we are moving beyond the polymer into
semi-finished and finished products which shape future performance for our
customers and our markets, provide environmental and societal benefit for
customers and drive value for our shareholders. Find out more
at www.victrexplc.com (http://www.victrexplc.com/)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAEASLLESEAEFA